Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 4/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.31 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.30 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.30 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764614 | 1.00 | CYP3A4 (0.65) | CYP3A4CRBNKITMETTRPV1 | |
| SCHEMBL2491321 | 0.86 | CYP3A4 (0.72) | CYP3A4CRBNKITMETTRPV1 | |
| SCHEMBL2491324 | 0.86 | CYP3A4 (0.72) | CYP3A4CRBNKITMETTRPV1 | |
| SCHEMBL10135112 | 0.85 | CYP3A4 (0.45) | CYP3A4TNFRSF1A | |
| SCHEMBL2489644 | 0.85 | CYP3A4 (0.73) | CYP3A4CRBNTRPV1TNFRSF1APADI4 | |
| SCHEMBL2489645 | 0.85 | CYP3A4 (0.73) | CYP3A4CRBNTRPV1TNFRSF1APADI4 | |
| SCHEMBL6765262 | 0.83 | CYP3A4 (0.64) | CYP3A4CRBNMETPADI4PIP4K2A | |
| SCHEMBL2488735 | 0.82 | CYP3A4 (0.71) | CYP3A4CRBNMETTRPV1PADI4 | |
| SCHEMBL2488740 | 0.82 | CYP3A4 (0.71) | CYP3A4CRBNMETTRPV1PADI4 | |
| SCHEMBL3240246 | 0.81 | CYP3A4 (0.70) | CYP3A4CRBNTRPV1TNFRSF1APADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379534-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | claimed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | claimed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | claimed |
| US-8383824-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2501679-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2379534-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011061243-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HCCS, EIF2AK2, RNASE1 | CYP3A4 60/4885CRBN 3075/4885KIT 3457/4885 |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | CYP3A4 978/4885CRBN 1341/4885KIT 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.